论文部分内容阅读
目的:评价舒利迭治疗B组稳定期慢性阻塞性肺疾病(COPD)患者的疗效及安全性。方法:200例B组稳定期COPD患者随机分为治疗组和对照组,在常规治疗的基础上,治疗组给予舒利迭治疗,疗程12个月。两组患者治疗前后CAT评分,肺功能,血C反应蛋白(CRP)、降钙素(PCT)水平比较。结果:168例患者完成试验,期间未发生舒利迭相关严重药物不良反应。治疗组急性加重次数(0.5±0.3)次/人少于对照组(0.8±0.4)次/人,差异有统计意义。(P<0.05)从治疗3月开始治疗组患者CAT评分、CRP水平逐渐降低,治疗12个月后治疗组分别为(13.0±3.4)分、(1.9±0.7)ng/ml低于对照组(15.6±2.3)分、(2.6±0.9)ng/ml,差异有统计学意义。(P<0.05)同时治疗组患者FEV1逐渐升高,治疗12个月后治疗组为(1.51±0.39)L高于对照组为(1.35±0.42)L,差异有统计学意义。(P<0.05)结论:舒利迭治疗B组稳定期COPD患者安全有效。
Objective: To evaluate the efficacy and safety of seretide in treatment of patients with stable chronic obstructive pulmonary disease (COPD) in group B. Methods: 200 patients with stable COPD in group B were randomly divided into treatment group and control group. On the basis of routine treatment, the treatment group was given seretide for 12 months. CAT scores, lung function, CRP and PCT levels in two groups before and after treatment were compared. RESULTS: A total of 168 patients completed the trial without significant adverse drug reactions to seretide. The number of acute exacerbations in the treatment group was (0.5 ± 0.3) times / person was less than that in the control group (0.8 ± 0.4) times / person, the difference was statistically significant. (P <0.05). CAT scores and CRP levels decreased gradually from the beginning of treatment in March to March in treatment group (13.0 ± 3.4) and (1.9 ± 0.7) ng / ml in control group after 12 months 15.6 ± 2.3) points, (2.6 ± 0.9) ng / ml, the difference was statistically significant. (P <0.05). The FEV1 level of the patients in the treatment group increased gradually at the 12th month after treatment (1.51 ± 0.39) L compared with that in the control group (1.35 ± 0.42) L, the difference was statistically significant. (P <0.05) Conclusion: Seretide treatment group B stable COPD patients safe and effective.